Patent US20030173540A1 successfully refreshed from Google Patents.
Patent EP0394905A2 successfully refreshed from Google Patents.
← Back to Patent Explorer
EP0394905A2 Expired / Lapsed EP ⏱️ 0.0 years remaining

Excitatory amino acid antagonists

Assignee: Aventis Pharmaceuticals Inc
•
Filing: 1990-04-23
•
Granted: —
•
Expires: 2010-04-23
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention is directed to pharmaceutical compositions containing 2-carboxylic indole derivatives. The compounds are excitatory amino acid antagonists.

Inventors

  • 👤 Francesco G. Salituro
  • 👤 Boyd L. Harrison
  • 👤 Bruce M. Baron

Bibliographic Details

Application Number —
Jurisdiction EP
Data Source google_patents
Last Synchronized 2026-11-08 13:50
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K31/403; A61K31/404; A61K31/405; A61P; A61P25/00; A61P25/04; A61P25/08; A61P25/20; A61P25/28; A61P9/00; A61P9/10

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 140 words
A pharmaceutical composition containing a compound of the Formula I, wherein X is represented by a C₁₋₄ alkyl, Z is represented by H, C₁₋₄ alkyl, phenyl, substituted phenyl, or an alkylphenyl substituent in which the phenyl ring may be optionally substituted; R is represented by a substituent selected from the group consisting of hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, CF₃, OCF₃, OH, NO₂, and CN; R₁ and R₂ are each independently represented by -OH, -OR₃ in which R₃ is represented by a C₁₋₄ alkyl, phenyl, substituted phenyl or an alkylphenyl substituent in which the phenyl ring may be optionally substituted, NR₄R₅ in which R₄ and R₅ are each independently represented by hydrogen or a C₁₋₄ alkyl, or OCH₂OR₃ in which R₃, is as defined above, the pharmaceutically acceptable basic addition salts thereof; and optionally a pharmaceutically acceptable carrier and/or diluent.
Claim 2
Dependent Claim 140 words
A pharmaceutical composition containing a compound of the Formula I, wherein X is represented by a C₁₋₄ alkyl, Z is represented by H, C₁₋₄ alkyl, phenyl, substituted phenyl, or an alkylphenyl substituent in which the phenyl ring may be optionally substituted; R is represented by a substituent selected from the group consisting of hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, CF₃, OCF₃, OH, NO₂, and CN; R₁ and R₂ are each independently represented by -OH, -OR₃ in which R₃ is represented by a C₁₋₄ alkyl, phenyl, substituted phenyl or an alkylphenyl substituent in which the phenyl ring may be optionally substituted, NR₄R₅ in which R₄ and R₅ are each independently represented by hydrogen or a C₁₋₄ alkyl, or OCH₂OR₃ in which R₃, is as defined above, the pharmaceutically acceptable basic addition salts thereof; and optionally a pharmaceutically acceptable carrier and/or diluent.
Claim 3
Dependent Claim 17 words
The composition according to claim 1 wherein X of Formula I is represented by an ethylene group.
Claim 4
Dependent Claim 19 words
The composition according to claim 1 or 2 wherein R₁ and R₂ of Formula I are represented by OH.
Claim 5
Dependent Claim 33 words
The composition according to any of claims 1 to 3 wherein R of Formula I is represented by a monosubstitution occurring at position 6, or a disubstitution occurring at positions 4 and 6.
Claim 6
Dependent Claim 23 words
The composition according to any of claims 1 to 4 for antagonizing the effects of excitatory amino acids upon the NMDA receptor complex.
Claim 7
Dependent Claim 15 words
The composition according to any of claims 1 to 4 for the treatment of epilepsy.
Claim 8
Dependent Claim 16 words
The composition according to any of claims 1 to 4 for the treatment of neurodegenerative diseases.
Claim 9
Dependent Claim 17 words
The composition according to any of claims 1 to 4 for preventing ischemic/hypoxic/hypoglycemic damage to cerebral tissue.
Claim 10
Dependent Claim 15 words
The composition according to any of claims 1 to 4 for the treatment of anxiety.
Claim 11
Dependent Claim 15 words
The composition according to any of claims 1 to 4 for producing an analgesic effect.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag